Recursion Pharmaceuticals, Inc.
- Jurisdiction
United States - ISIN
US75629V1044 (RXRX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. Read full profile
Stock price
Fundamentals
- Net revenue
€54.97M - Gross margin
-3.8% - EBIT
-€554.18M - EBIT margin
-1,008.2% - Net income
-€553.54M - Net margin
-1,007.1%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Dividends
No dividend payouts
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Gibson Christopher | Chief Executive Officer |
|
|
|
|
| Khan Najat | Chief R&D Commercial Officer |
|
|
|
|
| Gibson Christopher | Chief Executive Officer |
|
|
|
|
Earnings Calls
Latest earnings call: August 5, 2025
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Cathie Wood |
|
|
|
Buy |
| James Anderson |
|
|
|
Sell |